Parma Mobile App Cross Platform Development
BASIC
- Around 5 Screens.
- Around 5 Integrations
- Only simple validations on device
- No-obligation inquiry.
- Team consists of: Dev Team - 1 Developer (full time) QA Team - 1 Test Engineer (shared)
STANDARD
- Around 10 Screens
- Around 10 Integrations
- Simple business logic for Validations / Calculations / Chart Data etc.
- Some local storage of data
- Team consists of: Dev Team - 1 Developer (full time) QA Team - 1 Test Engineer (shared)
- 1 Project Manager (shared)
- 1 Team Lead (shared)
PREMIUM
- Around 20 Screens
- Around 20 Integrations
- Complex business logic like Interactive Charts, Animations, Validations, Conditions etc.
- Complete local storage of data used by App
- We will create suggestions on monthly basis for improvement for you.
Cross-Platform App Development Services & Solutions in Parma
We take your groundwork and create a market-ready app based on your needs while you focus on product and company growth.
Flutter is the fastest-growing cross-platform development framework. It was introduced in 2017 by Google and managed to gain great popularity among cross-platform programmers.
Parma News
Chinese vic-premier calls for boosting basic pharmaceutical research, sci-tech innovation
Noting the positive momentum of China's pharmaceutical innovation in recent years, Liu called for joint research efforts from enterprises, universities, research institutions and medical institutions, ...
Cheap Catalyst Turns Acids Into Pharmaceutical Gold
Photoactivated ketones show strong potential as hydrogen atom transfer photocatalysts, enabling the activation of carboxylic acids and the formation of new C–C, C–S, and C–Cl bonds. Carboxylic acids a ...
US may revise hormone replacement therapy warnings
FDA Commissioner open to revising HRT warning labels due to benefits beyond menopausal symptoms, despite past breast cancer concerns.
The paradox of market restriction for anti-TB drugs
Newer anti-TB drugs like Bedaquiline, Delamanid, and Pretomanid may be restricted to NTEP, impacting TB treatment accessibility.

